Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125461691 | 12546169 | 1 | I | 20141127 | 20160629 | 20160711 | 20160711 | PER | US-CELGENEUS-USA-2016067391 | CELGENE | 69.00 | YR | M | Y | 93.00000 | KG | 20160711 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125461691 | 12546169 | 1 | PS | ABRAXANE | PACLITAXEL | 1 | Intravenous drip | Y | N | 21660 | 125 | MG/M**2 | INJECTION FOR INFUSION | /wk | |||||
| 125461691 | 12546169 | 2 | SS | ABRAXANE | PACLITAXEL | 1 | Intravenous drip | Y | N | 21660 | 100 | MG/M**2 | INJECTION FOR INFUSION | /wk | |||||
| 125461691 | 12546169 | 3 | SS | PEGPH20 | HYALURONIDASE RECOMBINANT HUMAN | 1 | Intravenous drip | U | U | 0 | 3 | UG/KG | INJECTION FOR INFUSION | QOW | |||||
| 125461691 | 12546169 | 4 | SS | PEGPH20 | HYALURONIDASE RECOMBINANT HUMAN | 1 | Intravenous drip | U | U | 0 | 3 | UG/KG | INJECTION | /wk | |||||
| 125461691 | 12546169 | 5 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Intravenous drip | Y | N | 55974 | 1000 | MG/M**2 | INJECTION | /wk | |||||
| 125461691 | 12546169 | 6 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Intravenous drip | Y | N | 55974 | 800 | MG/M**2 | INJECTION | /wk | |||||
| 125461691 | 12546169 | 7 | C | LOVENOX | ENOXAPARIN SODIUM | 1 | Unknown | 0 | UNKNOWN | ||||||||||
| 125461691 | 12546169 | 8 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Unknown | 0 | UNKNOWN | ||||||||||
| 125461691 | 12546169 | 9 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Unknown | 0 | UNKNOWN | ||||||||||
| 125461691 | 12546169 | 10 | C | BENICAR | OLMESARTAN MEDOXOMIL | 1 | Unknown | 0 | UNKNOWN | ||||||||||
| 125461691 | 12546169 | 11 | C | CARDIZEM | DILTIAZEM HYDROCHLORIDE | 1 | Unknown | 0 | UNKNOWN | ||||||||||
| 125461691 | 12546169 | 12 | C | FLOMAX | TAMSULOSIN HYDROCHLORIDE | 1 | Unknown | 0 | UNKNOWN | ||||||||||
| 125461691 | 12546169 | 13 | C | AMBIEN | ZOLPIDEM TARTRATE | 1 | Unknown | 0 | UNKNOWN | ||||||||||
| 125461691 | 12546169 | 14 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Unknown | 0 | UNKNOWN | ||||||||||
| 125461691 | 12546169 | 15 | C | Oxycodone | OXYCODONE | 1 | Unknown | 0 | 5 | MG | UNKNOWN | Q4H | |||||||
| 125461691 | 12546169 | 16 | C | Ondansetron | ONDANSETRON | 1 | Unknown | 30 MILLIGRAM | 0 | UNKNOWN | |||||||||
| 125461691 | 12546169 | 17 | C | Normal Saline | SODIUM CHLORIDE | 1 | Intravenous drip | 1500 MILLIGRAM | 0 | INJECTION | |||||||||
| 125461691 | 12546169 | 18 | C | Vancomycin | VANCOMYCIN | 1 | Intravenous drip | 18000 MILLIGRAM | 0 | 1500 | MG | INJECTION | |||||||
| 125461691 | 12546169 | 19 | C | PIPERACILLIN AND TAZOBACTAM | PIPERACILLIN SODIUMTAZOBACTAM SODIUM | 1 | Intravenous drip | 0 | 4500 | MG | INJECTION | Q6H | |||||||
| 125461691 | 12546169 | 20 | C | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Unknown | 5 MILLIGRAM | 0 | UNKNOWN | |||||||||
| 125461691 | 12546169 | 21 | C | DRONABINOL. | DRONABINOL | 1 | Unknown | 0 | 2.5 | MG | UNKNOWN | BID | |||||||
| 125461691 | 12546169 | 22 | C | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | Intravenous drip | 0 | 2 | G | INJECTION FOR INFUSION | Q8H |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125461691 | 12546169 | 1 | Pancreatic carcinoma |
| 125461691 | 12546169 | 3 | Pancreatic carcinoma |
| 125461691 | 12546169 | 5 | Pancreatic carcinoma |
| 125461691 | 12546169 | 7 | Product used for unknown indication |
| 125461691 | 12546169 | 8 | Product used for unknown indication |
| 125461691 | 12546169 | 9 | Product used for unknown indication |
| 125461691 | 12546169 | 10 | Product used for unknown indication |
| 125461691 | 12546169 | 11 | Product used for unknown indication |
| 125461691 | 12546169 | 12 | Product used for unknown indication |
| 125461691 | 12546169 | 13 | Product used for unknown indication |
| 125461691 | 12546169 | 14 | Product used for unknown indication |
| 125461691 | 12546169 | 15 | Product used for unknown indication |
| 125461691 | 12546169 | 16 | Product used for unknown indication |
| 125461691 | 12546169 | 17 | Product used for unknown indication |
| 125461691 | 12546169 | 18 | Product used for unknown indication |
| 125461691 | 12546169 | 19 | Product used for unknown indication |
| 125461691 | 12546169 | 20 | Product used for unknown indication |
| 125461691 | 12546169 | 21 | Product used for unknown indication |
| 125461691 | 12546169 | 22 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125461691 | 12546169 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125461691 | 12546169 | Febrile neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125461691 | 12546169 | 1 | 20141121 | 20141223 | 0 | |
| 125461691 | 12546169 | 2 | 20141223 | 20150223 | 0 | |
| 125461691 | 12546169 | 3 | 20141120 | 20141124 | 0 | |
| 125461691 | 12546169 | 4 | 20141223 | 20150223 | 0 | |
| 125461691 | 12546169 | 5 | 20141121 | 20141223 | 0 | |
| 125461691 | 12546169 | 6 | 20141223 | 20150223 | 0 | |
| 125461691 | 12546169 | 7 | 20141120 | 0 | ||
| 125461691 | 12546169 | 8 | 20141120 | 0 | ||
| 125461691 | 12546169 | 10 | 2013 | 0 | ||
| 125461691 | 12546169 | 11 | 2013 | 0 | ||
| 125461691 | 12546169 | 22 | 20141205 | 20141219 | 0 |